Roche obesity drug from $2.7B deal starts showing potential

Preliminary Phase 2 data show Roche's CT-388 led to a 22.5% placebo-adjusted weight loss measured at 48 weeks. Based on these results, the pharmaceutical company plans to advance the GLP-1 and GIP agonist to a Phase 3 clinical trial in obesity.

Editor's Pick

Top Story Roche Obesity Drug's Phase 2 Results Are Competitive, But True Test May Come From Combo Studies Preliminary Phase 2 data show Roche's CT-388 led to a 22.5% placebo-adjusted weight loss measured at 48 weeks. Based on these results, the pharmaceutical company plans to advance the GLP-1 and GIP agonist to a Phase 3 clinical trial in obesity. Sponsored Enhance Patient Care Through Intelligent Communication Presented by RingCentral Calling a hospital or medical practice can be a stressful, frustrating experience. RingCentral seeks to make the patient experience as frictionless and efficient as possible. Click here to learn how.

Featured News

How One Leading DSO Used Analytics to Drive a 26% Increase in Crown Treatment Planning Rates [Sponsored] A recent webinar sponsored by Overjet offered insights from Affinity Dental Management executives on how AI-driven clinical intelligence software can transform DSOs. Which Digital Health Startups Will Win in 2026? Investors at Breyer Capital think 2026 could mark a turning point in digital health, as logistics become as important as scientific innovation. They highlighted three key trends shaping the market: shifting biotech constraints from biology to delivery, bottom-up product adoption by clinicians, and a wave of consolidation among AI startups. Wisp Acquires Sexual Health Platform TBD Health This is Wisp's first acquisition, for which the terms of the deal were not disclosed. It allows the company to expand into providing in-person care to complement its virtual support. Serious Illness Care Runs on Caregivers — It's Time to Act Like It Caregivers are a backbone of serious illness care, but they cannot carry the system alone. We have reached a point where failing to support them is indistinguishable from failing patients. Medicare Is Covering GLP-1s - It's Time to Cover the Care That Makes Them Sustainable We have to cover medical nutrition therapy for those who need it most, including Medicare beneficiaries. Almost all commercial payers are already doing this – the government needs to catch up.

Video   Video: Inside a New Recursion Drug Katie Couric lost her husband to colon cancer in 1998. Nearly 30 years later, colon cancer rates are rising sharply, especially among younger people, and scientists still don't fully understand why. Watch Couric chat with Najat Khan, CEO of Recursion Pharmaceuticals. Recursion is using AI to identify a promising compound that targets the underlying biology of the disease.

Sponsored Omaha ABA Therapy: Comparing the Top Providers Presented by Stride Autism Centers The right provider enables children to gain confidence, learn to express their needs and discover new ways to connect with the world around them. Learn More

Resources

sponsored Esperion Sets Its Sights on New Areas While Maintaining Commitment to Cardiovascular Health Presented by Esperion In a recent interview, Esperion President and CEO, Sheldon Koenig talks about the reality of statin intolerance and his company's expansion into new diseases. Read more

MedCity News • PO Box 901 • New York, NY unsubscribe